The alternative complement pathway is longitudinally associated with adverse cardiovascular outcomes

Summary

The alternative pathway of complement activation is highly reactive and can be activated spontaneously in the vasculature. Activation may contribute to vascular damage and development of cardiovascular disease (CVD). We aimed to investigate functional components of the alternative pathway in cardiovascular risk. We studied 573 individuals who were followed-up for seven years. At baseline, we measured the enhancer properdin; the rate-limiting protease factor D (FD); and a marker of systemic activation, Bb. Using generalised estimating equations, we investigated their longitudinal associations with cardiovascular events (CVE, N=89), CVD (N=159), low-grade inflammation (LGI), endothelial dysfunction (ED) and carotid intima-media thickness (cIMT). Furthermore, we investigated associations with incident CVE (N=39) and CVD (N=73) in 342 participants free of CVD at baseline. CVE included myocardial infarction, stroke, cardiac angioplasty and/or cardiac bypass. CVD additionally included ischaemia on an electrocardiogram and/or ankle-brachial index < 0.9. In adjusted analyses, properdin was positively associated with CVE (per 1SD, longitudinal OR=1.36 [1.07; 1.74], OR for incident CVE=1.53 [1.06; 2.20]), but not with CVD. Properdin was also positively associated with ED (β=0.13 [95 %CI 0.06; 0.20]), but not with LGI or cIMT. FD and Bb were positively associated with LGI (per 1SD, FD: β=0.21 [0.12; 0.29], Bb: β=0.14 [0.07; 0.21]), and ED (FD: β=0.20 [0.11; 0.29], Bb: β=0.10 [0.03; 0.18]), but not with cIMT, CVE or CVD. Taken together, this suggests that the alternative complement pathway contributes to processes of vascular damage, and that in particular a high potential to enhance alternative pathway activation may promote unfavourable cardiovascular outcomes in humans.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Alternative complement pathway - properdin - cardiovascular events - endothelial dysfunction

• References

• 1 Muscari A, Bozzoli C, Puddu GM. et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995; 98: 357-364.
• 2 Carter AM. Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica 2012; 2012: 402783.
• 3 Hertle E, van Greevenbroek MM, Stehouwer CD. Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia 2012; 55: 881-884.
• 4 Hertle E, van Greevenbroek MM, Arts IC. et al. Distinct associations of complement C3a and its precursor C3 with atherosclerosis and cardiovascular disease. The CODAM study. Thromb Haemost 2014; 111: 1102-1111.
• 5 Ricklin D, Hajishengallis G, Yang K. et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-797.
• 6 Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell Mol Med 2008; 12: 1074-1084.
• 7 Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006; 176: 1305-1310.
• 8 Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 2008; 223: 300-316.
• 9 Fischetti F, Tedesco F. Cross-talk between the complement system and endothe-lial cells in physiologic conditions and in vascular diseases. Autoimmunity 2006; 39: 417-428.
• 10 Zipfel PF, Heinen S, Jozsi M. et al. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 2006; 43: 97-106.
• 11 Bossi F, Bulla R, Tedesco F. Endothelial cells are a target of both complement and kinin system. Int Immunopharmacol 2008; 08: 143-147.
• 12 Kerr H, Richards A. Complement-mediated injury and protection of endothe-lium: lessons from atypical haemolytic uraemic syndrome. Immunobiology 2012; 217: 195-203.
• 13 Hertle E, Stehouwer CD, van Greevenbroek MM. The complement system in human cardiometabolic disease. Mol Immunol 2014; 61: 135-148.
• 14 Oikonomopoulou K, Ricklin D, Ward PA. et al. Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol 2012; 34: 151-165.
• 15 Lupu F, Keshari RS, Lambris JD. et al. Crosstalk between the coagulation and complement systems in sepsis. Thromb Res 2014; 133 (Suppl. 01) S28-31.
• 16 Morgan BP, Gasque P. Extrahepatic complement biosynthesis: where, when and why?. Clin Exp Immunol 1997; 107: 1-7.
• 17 Mavri A, Stegnar M, Krebs M. et al. Impact of adipose tissue on plasma plasmi-nogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999; 19: 1582-1587.
• 18 Prugger C, Luc G, Haas B. et al. Adipocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol 2012; 71: 478-486.
• 19 Luc G, Empana JP, Morange P. et al. Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study. Int J Obes 2010; 34: 118-126.
• 20 Moreno-Navarrete JM, Martinez-Barricarte R, Catalan V. et al. Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes 2010; 59: 200-209.
• 21 Yasuda M, Takeuchi K, Hiruma M. et al. The complement system in ischemic heart disease. Circulation 1990; 81: 156-163.
• 22 Bongrazio M, Pries AR, Zakrzewicz A. The endothelium as physiological source of properdin: role of wall shear stress. Mol Immunol 2003; 39: 669-675.
• 23 Somani R, Richardson VR, Standeven KF. et al. Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes. Diabetes Care 2012; 35: 894-899.
• 24 Lesher AM, Nilsson B, Song WC. Properdin in complement activation and tissue injury. Mol Immunol 2013; 56: 191-198.
• 25 Bergseth G, Ludviksen JK, Kirschfink M. et al. An international serum standard for application in assays to detect human complement activation products. Mol Immunol 2013; 56: 232-239.
• 26 Oppermann M, Baumgarten H, Brandt E. et al. Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosor-bent assays. J Immunol Methods 1990; 133: 181-190.
• 27 Pangburn MK. Analysis of the natural polymeric forms of human properdin and their functions in complement activation. J Immunol 1989; 142: 202-207.
• 28 Schwaeble WJ, Reid KB. Does properdin crosslink the cellular and the humoral immune response?. Immunol Today 1999; 20: 17-21.
• 29 Pauly D, Nagel BM, Reinders J. et al. A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS ONE 2014; 09: e96371.
• 30 Amato MC, Pizzolanti G, Torregrossa V. et al. Visceral Adiposity Index (VAI) Is Predictive of an Altered Adipokine Profile in Patients with Type 2 Diabetes. PLoS ONE 2014; 09: e91969.
• 31 van Greevenbroek MM, Jacobs M, van der Kallen CJ. et al. Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study). Int J Cardiol 2012; 154: 158-162.
• 32 van Bussel BC, Ferreira I, van de Waarenburg MP. et al. Multiple Inflammatory Biomarker Detection in a Prospective Cohort Study: A Cross-Validation between Well-Established Single-Biomarker Techniques and an Electrochemi-luminescense-Based Multi-Array Platform. PLoS ONE 2013; 08: e58576.
• 33 Wlazlo N, van Greevenbroek MM, Ferreira I. et al. Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: the CODAM Study. Diabetes Care 2014; 37: 1900-1909.
• 34 Jacobs M, van Greevenbroek MM, van der Kallen CJ. et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009; 39: 437-444.
• 35 Jacobs M, van Greevenbroek MM, van der Kallen CJ. et al. The association between the metabolic syndrome and peripheral, but not coronary, artery disease is partly mediated by endothelial dysfunction: the CODAM study. Eur J Clin Invest 2011; 41: 167-175.
• 36 Stam F, van Guldener C, Schalkwijk CG. et al. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 2003; 18: 892-898.
• 37 Engelen L, Ferreira I, Gaens KH. et al. The association between the -374T/A polymorphism of the receptor for advanced glycation endproducts gene and blood pressure and arterial stiffness is modified by glucose metabolism status: the Hoorn and CoDAM studies. J Hypertens 2010; 28: 285-293.
• 38 Sterne JA, White IR, Carlin JB. et al. Multiple imputation for missing data in epi-demiological and clinical research: potential and pitfalls. Br Med J 2009; 338: b2393.
• 39 Janssen KJ, Donders AR, Harrell Jr. FE. et al. Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol 2010; 63: 721-727.
• 40 Gauvreau D, Roy C, Tom FQ. et al. A new effector of lipid metabolism: complement factor properdin. Mol Immunol 2012; 51: 73-81.
• 41 Paglialunga S, Fisette A, Yan Y. et al. Acylation-stimulating protein deficiency and altered adipose tissue in alternative complement pathway knockout mice. Am J Physiol Endocrinol Metab 2008; 294: E521-529.
• 42 Peake PW, Kriketos AD, Campbell LV. et al. Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes. Int J Obes 2005; 29: 429-435.
• 43 Westerink J, Hajer GR, Kranendonk ME. et al. An oral mixed fat load is followed by a modest anti-inflammatory adipocytokine response in overweight patients with metabolic syndrome. Lipids 2014; 49: 247-254.
• 44 Cortes C, Ohtola JA, Saggu G. et al. Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement. Front Immunol 2012; 03: 412.
• 45 Kimura Y, Miwa T, Zhou L. et al. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 2008; 111: 732-740.
• 46 Steiner T, Francescut L, Byrne S. et al. Protective role for properdin in progression of experimental murine atherosclerosis. PLoS ONE 2014; 09: e92404.
• 47 Ruef J, Kuehnl P, Meinertz T. et al. The complement factor properdin induces formation of platelet-leukocyte aggregates via leukocyte activation. Platelets 2008; 19: 359-364.
• 48 Saggu G, Cortes C, Emch HN. et al. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol 2013; 190: 6457-6467.
• 49 Prentice RL, Zhao S, Johnson M. et al. Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases. Genome Med 2013; 05: 112.
• 50 Horvath Z, Csuka D, Vargova K. et al. Elevated C1rC1sC1inh levels independently predict atherosclerotic coronary heart disease. Mol Immunol 2013; 54: 8-13.
• 51 Gorsuch WB, Chrysanthou E, Schwaeble WJ. et al. The complement system in ischemia-reperfusion injuries. Immunobiology 2012; 217: 1026-1033.
• 52 Engstrom G, Hedblad B, Janzon L. et al. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil 2007; 14: 392-397.
• 53 Onat A, Hergenc G, Can G. et al. Serum complement C3: a determinant of car-diometabolic risk, additive to the metabolic syndrome, in middle-aged population. Metabolism 2010; 59: 628-634.